About Us

About Us

The Moving Fourth Steering Committee

We are the Moving Fourth Steering Committee – a group of healthcare professionals and a patient advocate with world-leading expertise in HIV. United by a vision of healthy living with HIV, our focus is to provide practical tools and recommendations for HIV care.

Dr Joop Arends

Internist, Infectious Diseases Physician, Founder HappiApp, Board Member HappiApp Foundation and Director PatientApp, The Netherlands

Dr Thomas Buhk

Internist, Infectious Diseases Physician, Centers for Infectious Diseases in Hamburg (ICH-Hamburg), Germany 

Mario Cascio

Programme Chair for Quality of Life, European AIDS Treatment Group (EATG), Italy 

Dr Adrian Curran

Internist, Infectious Diseases Physician, Department of Infectious Diseases, Vall d’Hebron University Hospital, Barcelona, Spain

Dr Giovanni Guaraldi (Chair)

Associate Professor of Infectious Disease and Head of the Modena HIV Metabolic Clinic (MHMC), Italy

Dr Eugenio Teofilo

Department of Internal Medicine at Hospital dos Capuchos, Lisboa, Portugal

Dr Guido van den Berk

Internist, Infectious Diseases Physician, Department of Internal Medicine, OLVG, City Hospital of Greater Amsterdam, The Netherlands

Christian Verger contributed to the First Chapter of Moving Fourth (2019), however discontinued his efforts with the Steering Committee thereafter and in the subsequent Chapters (2020, 2021).

Resources

Chapter 1 Publication | “Moving Fourth”: A Vision Toward Achieving Healthy Living with HIV Beyond Viral Suppression

A summary of the first chapter of the Moving Fourth initiative was published in AIDS Reviews in 2019.

Chapter 2 Publication | “Moving Fourth”: Introduction of a practical toolkit for shared decision-making to facilitate healthy living beyond HIV viral suppression

A summary of the second chapter of the Moving Fourth was published in AIDS Reviews in 2021.

Supporting Sources

Sleep disorders 
Fatigue & energy loss 
Stigma 

References

Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159-168. https://doi.org/10.1182/blood-2016-01-629790 PMid:27053535
Myeloma UK AL amyloidosis Essential Guide. Accessed May 30, 2022.
Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492.
NHS. Amyloidosis. Accessed May 26, 2022.
McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. The Patient-Patient-Centered Outcomes Research. 2018;11(2):207-16.
Stanford Health Care. AL (Primary) Amyloidosis. Accessed May 26, 2022.
John Hopkins Medicine. What is amyloidosis?. Accessed May 26, 2022.
Amyloidosis Foundation. AA Amyloidosis. Accessed May 26, 2022.
Amyloidosis Foundation. Hereditary Amyloidosis. Accessed May 26, 2022.
Amyloidosis Foundation. Wild-type Amyloidosis. Accessed May 26, 2022.
Mayo Clinic. Amyloidosis. Accessed May 26, 2022.
Myeloma UK. AL amyloidosis. Accessed May 26, 2022.
Merlini G, Dispenzieri A, Sanchorawala V, et al. Systematic immunglobulin light chain amyloidosis. Nature Review Disease Primers. 2018;4(1):38.
Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis. Bone Marrow Transplantation. 2006;38;7-15.